Poor osteosarcoma patient outcome is associated with overexpression of HER2 [76], which prompted evaluation of the HER2 antibody trastuzumab with chemotherapy to treat HER2-positive metastatic osteosarcoma [77]. Here, ERBB2 is linked to osteosarcoma.